FDA shares update on heart devices linked to multiple recalls and patient deaths

Certain intra-aortic balloon pumps (IABPs) manufactured by Datascope, a subsidiary of Getinge, have been involved in multiple recalls in 2023, including a series of Class I incidents associated with a risk of “serious injuries or death.”

To help healthcare providers track these ongoing concerns, the U.S. Food and Drug Administration (FDA) has published an open letter that puts all of the most relevant details together in one location.

The devices in question are the Cardiosave Hybrid and Rescue IABPs, designed to provide temporary support to a patient’s left ventricle. There have been six Class 1 recalls so far, the agency explained in its letter, and each one corresponds to a different reason that the devices unexpectedly stopped working. When this happens, it creates a risk of interrupting treatment, and the patient faces a heightened risk of experiencing a serious adverse event.

Cardiosave IABP Rescue

The Cardiosave Rescue Intra-Aortic Balloon Pump. 

These are the six reasons the devices are shutting down with no warning, complete with a link to the recall tied to each issue:

A total of six deaths have been linked to these ongoing concerns. The FDA recommends that healthcare providers using these devices monitor the situation closely. Issues of any kind should be reported directly to the agency, and devices can be returned to the manufacturer if customers wish to take that step. Otherwise, customers can still continue using the IABPs, but they should “have additional charged IABP devices available and ready.”

“The FDA continues to work with the manufacturer to evaluate these issues,” according to the agency’s letter. “While the FDA remains concerned about device shutdown and pump stop events, these devices may continue to be used to provide circulatory support when necessary. The FDA recognizes that alternative treatments are limited.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Radiology can participate only sporadically in CMS’s current conception of value-based care. Why?

Although advanced imaging exams have proven benefits in defining disease severity, new data indicate that more sophisticated studies might not impact outcomes as much as previously thought. 

While the ACC/AHA 2021 Chest Pain Assessment Guidelines included cardiac CT angiography as a top level recommendation, gaps in evidence still need to be filled.

Trimed Popup
Trimed Popup